治疗前血样中的复合T细胞生物标志物与免疫相关不良事件的检测相关。
A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events.
作者信息
Goswami Sangeeta, Siddiqui Bilal A, Subudhi Sumit K, Basu Sreyashi, Yadav Shalini S, Diab Adi, Sharma Padmanee
机构信息
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 7730, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 7730, USA.
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 7730, USA.
出版信息
Cancer Cell. 2022 Mar 14;40(3):249-251. doi: 10.1016/j.ccell.2022.02.015.
Finding biomarkers for predicting anti-tumor responses and immune-related adverse events (irAEs) with immune checkpoint therapy remains a challenge. Lozano et al. have developed a composite biomarker score that includes the frequency of effector-memory CD4 T cells and TCR clonality of CD4 T cells in peripheral blood as a potentially predictive biomarker of irAEs.
寻找用于预测免疫检查点疗法的抗肿瘤反应和免疫相关不良事件（irAEs）的生物标志物仍然是一项挑战。洛萨诺等人开发了一种复合生物标志物评分，其中包括外周血中效应记忆CD4 T细胞的频率和CD4 T细胞的TCR克隆性，作为irAEs的潜在预测生物标志物。
Zotero 插件